R_and_d - Inspire Pharmaceuticals

Clinical Development Pipeline

Product	Pre-clinical	Phase 1	Phase 2	Phase 3

Denufosol
for Cystic Fibrosis

PROLACRIA^TM
for Dry Eye*

AZASITE^®
for Blepharitis**

Glaucoma
Program

^* NDA filed and received two approvable letters from the FDA; PROLACRIA™ is the proposed
U.S. tradename for diquafosol tetrasodium ophthalmic solution 2%.

^** Currently approved for the treatment of bacterial conjunctivitis.

Pipeline Links

Denufosol Program Overview

Denufosol tetrasodium inhalation solution for cystic fibrosis - Phase 3

PROLACRIA^TM Program Overview

(diquafosol tetrasodium ophthalmic solution) 2% for dry eye - Phase 3; Approvable

AZASITE^® Program Overview

(azithromycin ophthalmic solution) 1% for blepharitis - Phase 2

Glaucoma Program Overview

INS115644 and INS117548 for glaucoma - Phase 1

Inspire